Ponatinib (sold under the brand name Iclusig) is an oral tyrosine kinase inhibitor (TKI) used to treat specific types of adult leukemia, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).It is mainly prescribed for patients whose cancer has the T315I mutation, which causes resistance to other TKIs, or who cannot tolerate or benefit from at least two prior TKI therapies. It is also used in combination with chemotherapy for newly diagnosed Ph+ ALL. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors, Tyrosine Kinase Inhibitors and VEGF inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include ponatinibum. Its PubChem CID is 24826799.
Ponatinib
| CAS No | 943319-70-8 |
|---|---|
| Molecular Formula | C29H27F3N6O |
| Molecular Weight | 532.60 g/mol |
| Synonyms | 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
It is mainly prescribed for patients whose cancer has the T315I mutation, which causes resistance to other TKIs, or who cannot tolerate or benefit from at least two prior TKI therapies.
The listed CAS number is 943319-70-8.
The listed molecular formula is C29H27F3N6O.
The listed molecular weight is 532.60 g/mol.
3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide.
The source lists ponatinibum.